This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

HomeMechanism of ActionEfficacySafetyDosingClinical ExperienceHow HYMPAVZI WorksHow HYMPAVZI WorksHYMPAVZI OverviewHow HYMPAVZI WorksEfficacyEfficacyStudy DesignPrimary EndpointLong-term ProtectionSecondary EndpointsSafetySafetyAdverse EventsSafetyDosingDosingDosing OverviewMeet the HYMPAVZI PenInjection OverviewWhy HYMPAVZIWhy HYMPAVZIAddresing Patient NeedsWhy HYMPAVZIResourcesResourcesMaterialsVideos

Click here for HYMPAVZI®▼ (marstacimab) Prescribing Information.

HYMPAVZI is generally well tolerated1,2

The overall safety profile of HYMPAVZI is based on data from clinical studies. HYMPAVZI is generally well tolerated, with the majority of adverse events being mild to moderate in severity. The most serious adverse drug reaction
reported from the clinical studies was thrombosis (0.9%)1,2 

Adverse reactions from the BASIS study and the OLE study2
Adverse reaction Frequency
Headache Common (≥1/100 to <1/10)
Hypertension Common (≥1/100 to <1/10)
Rasha Uncommon (≥1/1000 to <1/100)
Thromboembolic events (thrombosis)b Uncommon (≥1/1000 to <1/100)
Pruritus Common (≥1/100 to <1/10)
Injection site reactionsa* Very common (≥1/10)

a. see ‘Description of selected adverse reactions’ in the Summary of Product Characteristics 
b. ADR reported in the open-label extension study post-data cut off.

Only 11.2% of patients reported ISRs2

The majority of injection site reactions observed in clinical studies with HYMPAVZI were mild to moderate, and did not lead to dose adjustment or discontinuation.*

0% discontinuation1

No patients discontinued HYMPAVZI due to treatment-related adverse reactions in the active treatment phase.

Data reflect exposure of 116 patients to HYMPAVZI administered once weekly. The safety analysis also includes data from the 87 patients who enrolled in the OLE study. Median duration of exposure was 518.5 days (range: 28–847 days).2

*ISRs included injection site bruising, injection site erythema, injection site haematoma, injection site induration, injection site oedema, injection site pain, injection site pruritus,
and injection site swelling.2

OLE, open-label extension. ADR, adverse drug reaction. ISR, injection site reaction

References:

1. Matino D, et al. Blood. 2025;146(14):1654–1663.
2. HYMPAVZI (marstacimab) Summary of Product Characteristics. Kicker Header of this card goes here

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

 Button LoadingKicker Header of this card goes here

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

 Button LoadingBadgeKicker Header of this card goes here

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

 Button Loading

Optional footnote area for disclaimers etc.

The efficacy of HYMPAVZI was evaluated in the BASIS study

Learn more about HYMPAVZI efficacy.

 EfficacyLoadingPre-filled fixed dose pen. Once-weekly dosing1

Understand the HYMPAVZI dosing schedule and see how HYMPAVZI can be administered.

 DosingLoading
PP-HYM-GBR-0323. February 2026

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2026 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-13934. January 2026
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-GBR-12070. April 2025​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-13971. December 2025

YesNo
You are now leaving PfizerPro

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

PP-UNP-GBR-12107. April 2025
​​​​​​​